A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

After what Bavarian Nordic described as “intense negotiations,” the Danish vaccines maker has agreed to be acquired by a ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit ...

With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear ...

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...